Illumina, Inc. (NASDAQ:ILMN) Holdings Decreased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 17.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 103,120 shares of the life sciences company’s stock after selling 22,165 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.07% of Illumina worth $13,448,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. Bank of Montreal Can increased its holdings in shares of Illumina by 6.1% in the 3rd quarter. Bank of Montreal Can now owns 151,254 shares of the life sciences company’s stock valued at $19,681,000 after purchasing an additional 8,730 shares during the period. Private Trust Co. NA lifted its position in Illumina by 81.2% in the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after buying an additional 212 shares in the last quarter. Harvest Fund Management Co. Ltd lifted its position in Illumina by 53.1% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 7,378 shares of the life sciences company’s stock worth $962,000 after buying an additional 2,558 shares in the last quarter. Westfield Capital Management Co. LP acquired a new stake in shares of Illumina during the 3rd quarter valued at $370,000. Finally, Senvest Management LLC grew its holdings in shares of Illumina by 0.3% during the 3rd quarter. Senvest Management LLC now owns 895,760 shares of the life sciences company’s stock valued at $116,816,000 after acquiring an additional 2,990 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Price Performance

Shares of Illumina stock opened at $144.15 on Monday. The firm has a fifty day moving average price of $141.88 and a two-hundred day moving average price of $126.03. Illumina, Inc. has a fifty-two week low of $99.23 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The company has a market cap of $22.86 billion, a PE ratio of -14.47 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period last year, the business earned $0.33 earnings per share. Analysts expect that Illumina, Inc. will post 4.11 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Piper Sandler cut their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. HSBC upgraded Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. Daiwa Capital Markets raised shares of Illumina from a “neutral” rating to a “buy” rating and raised their price objective for the company from $120.00 to $154.00 in a research report on Friday, August 16th. Daiwa America raised shares of Illumina to a “strong-buy” rating in a research report on Friday, August 16th. Finally, Argus upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Wednesday, August 28th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $164.00.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.